Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours

This article was originally published here

The FDA granted Priority Review for the NDA, which provides for a six-month review, and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August

The post Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply